ReviewFrontiers in medicine2026
Endocrinology concepts for diabetic retinopathy care: bridging systemic metabolic control with retinal disease management and patient education.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a leading cause of vision loss and a common microvascular complication of diabetes mellitus. Although diagnosis and management are typically guided by retinal findings, systemic metabolic factors-including glycemic control, diabetes duration, blood pressure, renal function, lipid status, and overall complication burden-play a central role in disease development and progression. Clinical decision-making often remains fragmented across endocrinology, primary care, and ophthalmology, contributing to variability in screening, referral, treatment selection, and patient education. This review proposes an integrated framework that applies endocrinology as a lens through which to better understand and manage diabetic retinopathy. The approach begins with a classification of systemic diabetes and metabolic disorders, then aligns these metabolically defined patient profiles with retinal diagnosis, monitoring, and stage-appropriate treatment strategies. Evidence is drawn from landmark endocrinology studies defining epidemiologic cohorts, diagnostic validation studies, and major randomized clinical trials as the basis for best practices in ophthalmological care. The goal is not only to synthesize evidence for clinicians, but also to support development of a concise patient-facing educational roadmap, presented as supplementary material, that summarizes disease progression, screening, treatment options, and anticipated next steps for patients. By integrating longitudinal endocrinology data with findings in ophthalmology, this framework may provide a strong rationale for interdisciplinary care, improve treatment outcomes, and promote more effective engagement of patients and their ophthalmologists in prevention and treatment of diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.